About Us

About TipRanks Contact Us

Working with TipRanks

Enterprise Solutions Tools for Trading Platforms Data for Hedge Funds Best Online Brokers Become an Affiliate

News Smart Portfolio Expert Center

TOOLS

STOCKS

ADVANCED RESEARCH

Invest Like a Pro with Unique Data & Simplifed Tools Try Now

Fastest Growing Websites

Top Wall Street Analysts

Top Financial Bloggers

Top Corporate Insiders

Popular

Top Hedge Fund Managers

Top Individual Investors

Dividend Yield Calculator

Daily Stock Ratings

Daily Insider Transactions

Stock ComparisonPOPULAR COMPARISONS

My Portfolio Analysis

Stock Market Holidays

Market News

Stock Analysis & Ideas

Earnings Reports Insights

Pre-Market Breakdowns

AFMD Stock Latest News

Press ReleasesAffimed Reports on Corporate Progress and Provides Regulatory Update for AFM13

18d ago

AFMD

$Affimed Announces Approval of Clinical Trial Application in France for a Phase 1 Study of AFM28 in Relapsed/Refractory Acute Myeloid Leukemia$

Press ReleasesAffimed Announces Approval of Clinical Trial Application in France for a Phase 1 Study of AFM28 in Relapsed/Refractory Acute Myeloid Leukemia

1M ago

AFMD

The FlyAffimed’s Phase 1 study of AML candidate approved in France

1M ago

AFMD

Market NewsAffimed Plunges after Detailing New Plans

2M ago

AFMD

The FlyAffimed price target lowered to $8 from $12 at Truist

2M ago

AFMD

The FlyAffimed presents updated data from AFM28

2M ago

AFMD

Affimed Presents Updated Data for AFM28 Demonstrating Efficient Elimination of Leukemic Stem and Progenitor Cells in Combination with Allogeneic NK cells in Preclinical Models of Acute Myeloid Leukemia and Myelodysplastic Syndrome at the Annual ASH 2022 Meeting

Press ReleasesAffimed Presents Updated Data for AFM28 Demonstrating Efficient Elimination of Leukemic Stem and Progenitor Cells in Combination with Allogeneic NK cells in Preclinical Models of Acute Myeloid Leukemia and Myelodysplastic Syndrome at the Annual ASH 2022 Meeting

2M ago

AFMD

The FlyAffimed initiated with a Buy at H.C. Wainwright

2M ago

AFMD

The FlyPiper Sandler keeps Overweight rating on Affimed, lowers price target to $6

2M ago

AFMD

The FlyAffimed provides data from Phase 1/2 study AFM13 precomplexed with cbNK cells

2M ago

AFMD

The FlyAffimed reports topline data from AFM13 monotherapy Phase 2 REDIRECT study

2M ago

AFMD

$Affimed Reports Topline Data from AFM13 Monotherapy Phase 2 REDIRECT Study in Patients with Relapsed or Refractory Peripheral T Cell Lymphoma$

Press ReleasesAffimed Reports Topline Data from AFM13 Monotherapy Phase 2 REDIRECT Study in Patients with Relapsed or Refractory Peripheral T Cell Lymphoma

2M ago

AFMD

Affimed Provides Updated Clinical Data from Phase 1/2 Study of AFM13 Precomplexed with Cord Blood-Derived NK Cells at the ASH 2022 Annual Meeting

Press ReleasesAffimed Provides Updated Clinical Data from Phase 1/2 Study of AFM13 Precomplexed with Cord Blood-Derived NK Cells at the ASH 2022 Annual Meeting

2M ago

AFMD

Press ReleasesAffimed to Host Investor Event Highlighting AFM13 Clinical Development at 2022 ASH Annual Meeting

2M ago

AFMD

Press ReleasesAffimed Reports Third Quarter 2022 Financial Results and Highlights Recent Clinical and Corporate Progress

2M ago

AFMD

The FlyBiotech Alert: Searches spiking for these stocks today

3M ago

AFMD

MRUS

The FlyPiper says unexpected response in 1st dose cohort bodes well for AFM24-NK study

3M ago

AFMD

The FlyAffimed provides data update from Phase 1/2a trials of AFM24

3M ago

AFMD

Affimed Provides Data Update from Two Phase 1/2a Trials with its Innate Cell Engager AFM24 in Solid Tumor Patients at the 37th SITC Annual Meeting

Press ReleasesAffimed Provides Data Update from Two Phase 1/2a Trials with its Innate Cell Engager AFM24 in Solid Tumor Patients at the 37th SITC Annual Meeting

3M ago

AFMD

Press ReleasesAffimed to Report Third Quarter 2022 Financial Results & Corporate Update on November 15, 2022

3M ago

AFMD

Affimed and Artiva Biotherapeutics Announce Partnership to Advance Combination Therapy of Innate Cell Engager (ICE®) AFM13 and Off-the-Shelf Allogeneic NK Cell Therapy AB-101

Press ReleasesAffimed and Artiva Biotherapeutics Announce Partnership to Advance Combination Therapy of Innate Cell Engager (ICE®) AFM13 and Off-the-Shelf Allogeneic NK Cell Therapy AB-101

3M ago

AFMD

Affimed Announces Presentation of Phase 1/2 Data from AFM13 in Combination with Allogeneic NK Cells and Preclinical AFM28 Data at ASH 2022 Annual Meeting

Press ReleasesAffimed Announces Presentation of Phase 1/2 Data from AFM13 in Combination with Allogeneic NK Cells and Preclinical AFM28 Data at ASH 2022 Annual Meeting

3M ago

AFMD

Press ReleasesAffimed to Present at the 2022 Jefferies London Healthcare Conference

3M ago

AFMD

Affimed Announces Two Clinical Update Presentations on its Novel Bispecific Innate Cell Engager AFM24 at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

Press ReleasesAffimed Announces Two Clinical Update Presentations on its Novel Bispecific Innate Cell Engager AFM24 at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

4M ago

AFMD

Affimed To Provide a Clinical Update on AFM24 Monotherapy Dose-escalation at European Society for Medical Oncology (ESMO) Congress 2022

Press ReleasesAffimed To Provide a Clinical Update on AFM24 Monotherapy Dose-escalation at European Society for Medical Oncology (ESMO) Congress 2022

5M ago

AFMD

Press ReleasesAffimed to Present at Upcoming Investor Conferences

5M ago

AFMD

Press ReleasesAffimed Reports Second Quarter 2022 Financial Results and Highlights Recent Operational Progress

6M ago

AFMD

Press ReleasesAffimed to Report Second Quarter 2022 Financial Results & Corporate Update on August 11, 2022

6M ago

AFMD

Affimed Presents Preclinical Data of Novel Innate Cell Engager AFM28 at the Annual Meeting of the European Hematology Association (EHA)

Press ReleasesAffimed Presents Preclinical Data of Novel Innate Cell Engager AFM28 at the Annual Meeting of the European Hematology Association (EHA)

8M ago

AFMD